Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET

Company Participants

Kate Rausch - Vice President, Investor Relations & Corporate Affairs
Paul Bolno - President & Chief Executive Officer
Anne-Marie Li-Kwai-Cheung - Chief Development Officer
Kyle Moran - Chief Financial Officer
Erik Ingelsson - Chief Scientific Officer

Conference Call Participants

Tiago Fauth - Wells Fargo
Joseph Schwartz - Leerink Partners
Steven Seedhouse - Raymond James
Luca Issi - RBC
Salim Syed - Mizuho
Joon Lee - Truist

Operator

Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded and webcast.

I'll now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.

Kate Rausch

Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2024 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer; Anne-Marie Li-Kwai-Cheung, Chief Development Officer; and Kyle Moran, Chief Financial Officer. Erik Ingelsson, Chief Scientific Officer; Chandra Vargeese, Chief Technology Officer; and Ginnie Yang, SVP of Translational Medicine, will also be available for questions following the call.

The press release issued this morning is available on the Investors section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul.

Paul Bolno

Thanks, Kate. Good morning, and thank you all for joining us on today's call. We have made incredible progress throughout the first half of this year, both in demonstrating the continued translation of our unique novel platform in the clinic and advancing our high-impact RNA medicines pipeline across modalities.

A highlight of the second quarter was the positive results from the SELECT-HD clinical trial for WVE-003 for Huntington's disease. And I'll begin today with some remarks on this program and progress we've made since we announced them. The clinical data, which we announced in June, serve as a testament to our best-in-class chemistry capabilities where our proprietary PN and stereochemistry enabled WVE-003 to achieve potent and durable mutant protein lowering while attaining exquisite specificity with wild-type preservation. This also led to a statistically significant correlation between mutant Huntington lowering and slowing of caudate atrophy, a potential clinical endpoint for accelerated approval.